SEC Form 4 · accession 0000899243-15-003422
Inhibitor Therapeutics, Inc. · INTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stefan Cross
Director
Period of report
Aug 14, 2015
Accepted (ET)
Aug 18, 2015 · 4:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001042418
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Aug 14, 2015 | A | 300,000 | A | — | — | Common Stock | 300,000 | 300,000 | D |
Explanation of responses
- F1Each restricted stock unit ("RSU") represents a right to receive one share of the issuer's common stock.
- F2The RSUs were issued to the reporting person on August 14, 2015, pursuant to a grant under the issuer's 2014 Equity Incentive Plan. The RSUs will vest in the first open window after the earlier to occur of (i) September 5, 2017 and (ii) approval by the United States Food and Drug Administration of any of the issuer's products that utilize its patented formulation of the drug itraconazole, known as SUBATM-Itraconazole.